Table 2.

Outcomes of patients with ipilimumab re-induction therapy

Age, years	Best response at week 12 (RECIST)	Duration between 1st restaging (week 12) and re-induction therapy (days)	Response at 1st restaging after re-induction (RECIST)	Best overall response after re-induction (RECIST)	Time from 1st dose to death/follow-up (months)	Alive
74	PR	91	SD	SD	17.1	Yes
56	PR	232	PR	CR	25.5	Yes
73	PR	217	PD	SD	24.8	Yes

RECIST response evaluation criteria in solid tumors, PR partial response, SD stable disease, PD progressive disease